OBJECTIVES: This study aimed to observe the expressions of Y box-binding protein-1 (YB-1) and P-glycoprotein (P-gp) in primary ovarian tumor and to determine whether they act as biomarkers for survival in epithelial ovarian cancer. METHODS: The expressions of YB-1 and P-gp were examined immunohistochemically in 59 patients who were treated from 1997 to 2000 at Kurume University Hospital. Samples were paraffin-embedded primary ovarian cancer tissue taken from the surgical specimens. RESULTS: Of the 59 primary ovarian tumors examined, 32 (54.2%) and 18 (30.5%) were positive for YB-1 and P-gp, respectively. Co-expression of these two proteins was observed in 20.3% (12/59) cases. Patients showing this co-expression had a worse 3-year survival than those without co-expression (40.0% vs. 73.1%, P = 0.0447). This co-expression significantly correlated with poor prognosis according to multivariate analysis (P = 0.0007). CONCLUSION: Co-expression of YB-1 and P-gp emerged as a promising relevant biomarker for unfavorable prognosis in ovarian cancer.
OBJECTIVES: This study aimed to observe the expressions of Y box-binding protein-1 (YB-1) and P-glycoprotein (P-gp) in primary ovarian tumor and to determine whether they act as biomarkers for survival in epithelial ovarian cancer. METHODS: The expressions of YB-1 and P-gp were examined immunohistochemically in 59 patients who were treated from 1997 to 2000 at Kurume University Hospital. Samples were paraffin-embedded primary ovarian cancer tissue taken from the surgical specimens. RESULTS: Of the 59 primary ovarian tumors examined, 32 (54.2%) and 18 (30.5%) were positive for YB-1 and P-gp, respectively. Co-expression of these two proteins was observed in 20.3% (12/59) cases. Patients showing this co-expression had a worse 3-year survival than those without co-expression (40.0% vs. 73.1%, P = 0.0447). This co-expression significantly correlated with poor prognosis according to multivariate analysis (P = 0.0007). CONCLUSION: Co-expression of YB-1 and P-gp emerged as a promising relevant biomarker for unfavorable prognosis in ovarian cancer.
Authors: Karsten Jürchott; Ralf-Jürgen Kuban; Till Krech; Nils Blüthgen; Ulrike Stein; Wolfgang Walther; Christian Friese; Szymon M Kiełbasa; Ute Ungethüm; Per Lund; Thomas Knösel; Wolfgang Kemmner; Markus Morkel; Johannes Fritzmann; Peter M Schlag; Walter Birchmeier; Tammo Krueger; Silke Sperling; Christine Sers; Hans-Dieter Royer; Hanspeter Herzel; Reinhold Schäfer Journal: PLoS Genet Date: 2010-12-02 Impact factor: 5.917
Authors: Frank Tacke; Nicolas Kanig; Abdelaziz En-Nia; Thilo Kaehne; Christiane S Eberhardt; Victoria Shpacovitch; Christian Trautwein; Peter R Mertens Journal: BMC Cancer Date: 2011-05-20 Impact factor: 4.430
Authors: Edgar Dahl; Abdelaziz En-Nia; Frank Wiesmann; Renate Krings; Sonja Djudjaj; Elisabeth Breuer; Thomas Fuchs; Peter J Wild; Arndt Hartmann; Sandra E Dunn; Peter R Mertens Journal: BMC Cancer Date: 2009-11-24 Impact factor: 4.430
Authors: Li Pu; Shi Jing; Guo Bianqin; Liu Ping; Liang Qindong; Liu Chenggui; Cheng Feng; Kuang Wenbin; Wang Qin; Dong Jinyu; Xia Qianfeng; Liu Yu; Tu Zhiguang Journal: Hepat Mon Date: 2013-07-03 Impact factor: 0.660